Glioblastoma Patient Derived Xenograft (PDX) Models
Glioblastoma (GBM) is the most common primary brain tumor. While many significant advances have been made understanding key genetic drivers of the disease, glioblastoma remains lethal with a 5-year survival of only 6.8%. Many factors contribute to the low survival rate- principal amongst them is a lack of relevant preclinical models. TD2 has partnered with the Mayo Clinic to offer its drug development partners access to 108 well characterized glioblastoma PDX mouse models. The PDX models recapitulate key genomic aspects of GBM including EGFR alterations, TERT promoter mutations, and CDKN2A deletions.
- MOA-Based Filters using selections driven by your drug’s specific mechanism of action and subsequent interrogation
- Diverse tissue types including fixed tissue for analysis of novel markers
- Assessment of tumor progression as single agents and in combination with standard therapies via orthotopic primary tumor models
- Well-established protocols that ensure an extremely high post-surgery survival rate
- Data-rich and highly characterized models with standard of care